Lowell, United States
Rapid Micro Biosystems is a leading company in automated microbial contamination detection for pharmaceutical manufacturing. Founded in 2006, it provides innovative automation solutions for the fast and safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables.
The company's flagship product, the Growth Direct® System, modernizes traditional quality control microbiology testing workflows used in pharmaceutical manufacturing. This platform aims to bring the quality control lab to the manufacturing floor, offering faster results, greater accuracy, increased operational efficiency, and better compliance with data integrity regulations.
Rapid Micro Biosystems is headquartered in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. Its recent $81.00M Private Equity Round investment on March 16, 2021, saw participation from notable investors such as D1 Capital Partners, BlackRock, T. Rowe Price, Adage Capital Management, CaaS Capital Management, and Sunley House Capital Management.
The company's commitment to customer-driven solutions, respect for diversity, determination to overcome challenges, and teamwork reflects its dedication to quality and innovation in the biotechnology, manufacturing, and pharmaceutical industries.
